Edelman wins Pfizer drug launch PR

Pfizer has awarded PR for a new nicotine-addiction treatment to Edelman.

Edelman's Frankfurt office pitched successfully for the work, which includes launch preparations and product communications for the treatment, which is likely to be given the brand name Champix.  The active ingredient, Vareniclin, is the product of Pfizer's research and development and is expected to gain its licence for Europe by the end of this year, with a market launch in Germany planned for early 2007.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in